Anti-CD20 Antibody Treatment for Progressive Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive multiple sclerosis (MS) are limited in effectiveness, with existing therapies providing only modest benefits in reducing relapse rates and preventing disability progression.
Innovation Solution
Administration of an effective amount of an anti-CD20 antibody, specifically targeting patients with certain characteristics such as age less than 55 years, presence of gadolinium staining lesions, at least a one-point increase in Expanded Disability Status Scale (EDSS) over two years, and a Multiple Sclerosis Severity Score (MSSS) greater than 5 points.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently approved treatments for RRMS are used, then relapse rate is reduced by approximately 30%, but the benefit is relatively modest and does not fully prevent disability accumulation in progressive MS
Solution Approach 1:
The patent changes the therapeutic target from CD4+ Th1 T cells (current treatments) to CD20+ B cells (anti-CD20 antibody), representing a fundamental parameter change in the immunomodulatory approach. This enables the treatment to be effective in progressive MS where inflammation is mediated by different mechanisms, thus resolving the contradiction between treatment effectiveness and adaptability to progressive MS
2Reliability
If existing immunomodulatory agents are used, then some disease activity is reduced, but they aggravate MS in certain cases and do not prevent disability progression
Solution Approach 1:
The patent extracts and targets specifically the B cell component (CD20+ cells) of the immune response in MS, separating it from the broader immunomodulatory approach of existing agents. By selectively depleting B cells through anti-CD20 antibody while sparing other immune components, the treatment achieves disease control without the aggravation effects seen with non-specific immunomodulators
3Ease of operation
If current treatments are applied to progressive MS patients, then some symptomatic relief is achieved, but disability progression continues and treatment benefits are limited
Solution Approach 1:
The patent takes preliminary action by targeting and depleting pathogenic B cells before they can cause further damage and disability progression. The anti-CD20 antibody prevents the formation of new lesions and blocks the inflammatory cascade at its source, rather than merely managing symptoms after damage has occurred, thus preventing disability progression while maintaining ease of administration
Data Source
AI summary
The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.